Product launch at Medica 2011

RNS Number : 3370S

EKF Diagnostics Holdings PLC

18 November 2011

 



EKF Diagnostics Holdings plc

("EKF" or "the Company")

EKF product launch at Medica 2011

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, announces the launch of a new product at the Medica 2011 conference in Dusseldorf, Germany: the Quo-Lab HbA1c analyser.

Quo-LabHbA1c analyser

The Quo-Lab product is billed as a revolution in HbA1c measurement because it combines world-leading accuracy with low cost, easy-to-use technology and has been developed to provide a point of care device that meets the needs of clinics and laboratories in developing countries where diabetes is an increasingly large public health issue and resources are limited.

Quo-Lab, which was designed by EKF subsidiary Quotient Diagnostics, is small and lightweight and uses a simple procedure to deliver lab-accurate results within four minutes. The first Quo-Lab analysers will be ready for shipping in Q1 2012.

More details on Quo-Lab can be found on the EKF website: www.ekfdiagnostics.co.uk

EKF will be demonstrating Quo-Lab at stand C94 in Hall 3 at Medica 2011 in Dusseldorf from 16^th-19^th November.

Enquiries:

EKF Diagnostics Holdings plc	Tel: [phone]
David Evans, Executive Chairman	Mob: [phone]
Julian Baines, CEO	Mob: [phone]
Collins Stewart Europe Limited	Tel: [phone]
Mark Dickenson / Jamie Adams
Walbrook PR Limited	Tel: [phone]
Paul McManus	Mob: [phone] or [e-mail]
Fiona Henson	Mob: [phone] or [e-mail]

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom.

For more information please visit the website: www.ekfdiagnostics.co.uk

 

END

 

 

NRAEAFFXFFLFFAF